— Abbott Diabetes Care has notified patients and clinicians that some FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose sensors may report falsely low glucose readings. Internal testing traced the problem to a single production line, and the company says roughly 3 million sensors were affected worldwide, with about 1.5 million estimated to have been used or expired. Abbott linked the faulty readings to incidents that include seven deaths (all reported outside the United States) and 736 serious injuries, and it is urging users to check affected devices and stop using any confirmed units immediately. The company said it will replace affected sensors at no charge and does not expect major supply disruptions.
Key Takeaways
- About 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors are potentially affected, according to Abbott’s notification.
- Internal testing attributed the issue to sensors produced on a single production line; roughly 1.5 million of the affected units are estimated to have been used or expired.
- Seven deaths have been reported in connection with the issue; all occurred outside the United States.
- There are 736 reported severe injuries worldwide, with 57 of those reported within the U.S.
- Abbott advises users to visit FreeStyleCheck.com to determine if their sensor is affected and to stop using and dispose of any confirmed faulty devices.
- The company states it will replace affected sensors at no cost and expects to continue production without major supply interruptions.
Background
Continuous and intermittently scanned glucose sensors such as Abbott’s FreeStyle Libre line are widely used by people with diabetes to measure interstitial glucose and guide decisions on carbohydrate intake and insulin dosing. These devices are intended to reduce the need for fingerstick testing and to provide near-real-time trend data to help avoid dangerous highs and lows.
Manufacturing and quality-control lapses in medical-device production can have outsized effects because devices are distributed at scale and used to make immediate treatment choices. Regulators and device makers have previously issued recalls when software, sensors or adhesives degraded performance; those events have prompted audits and process changes across the industry.
Main Event
Abbott’s internal review identified a production line anomaly that, the company says, can cause some FreeStyle Libre 3-family sensors to display incorrectly low glucose values. In a company statement, Abbott said the incorrect low readings could lead users to consume excess carbohydrates or skip or delay insulin doses—responses that carry both short-term and longer-term health risks.
The company estimates that about 3 million sensors from the affected runs were shipped, and that roughly half of those—1.5 million—have already been used or expired. Abbott told customers that if a device check indicates their sensor is affected they should immediately discontinue use and dispose of the unit, and the company will provide a free replacement.
Of the reported adverse outcomes, Abbott and reporting agencies have logged seven deaths outside the U.S. and 736 severe injuries globally; 57 severe injuries were reported within the United States. Abbott said it is cooperating with regulators and providing guidance to clinicians, while continuing production and planning replacements to limit patient impact.
Analysis & Implications
False low glucose readings pose a distinct clinical risk: patients and caregivers who believe glucose is low may consume extra carbohydrates or withhold insulin, actions that can destabilize glycemic control. Over time, repeated mismanagement can increase the risk of both acute events and long-term complications in people with diabetes. The immediate concern is preventing hypoglycemia-mismanagement and ensuring affected users have reliable alternatives while replacements are arranged.
Regulatory scrutiny is likely to follow. Large-scale device faults that result in serious injury or death typically trigger deeper inspections of manufacturing controls and quality systems. Agencies may demand production-site audits, corrective and preventive action plans, and expanded postmarket surveillance; such steps could affect Abbott’s timelines even if the company anticipates continued supply.
For health systems and clinicians, the episode raises operational questions about patient outreach, device verification and bridging strategies for affected patients. Clinicians will need to balance the risks of continuing use against the logistical and clinical costs of switching patients to alternative monitoring methods, including increased fingerstick testing or temporary use of competitor continuous glucose monitors (CGMs).
Comparison & Data
| Metric | Count |
|---|---|
| Potentially affected sensors | 3,000,000 |
| Estimated used/expired | 1,500,000 |
| Reported deaths | 7 (all outside U.S.) |
| Reported severe injuries (global) | 736 |
| Reported severe injuries (U.S.) | 57 |
The table shows the scale of the recall and the distribution of reported harms. While the number of affected devices is large, the confirmed severe harms represent a small fraction of units distributed; nonetheless, each reported injury or death prompts both clinical concern and regulatory attention. Hospitals and clinics should use device-check tools and patient registries to identify impacted individuals quickly.
Reactions & Quotes
“Internal testing determined that some sensors may provide incorrect low glucose readings,”
Abbott Diabetes Care (company statement)
Abbott’s statement emphasizes the mechanism of error and the immediate mitigation step for patients: check devices and stop using any confirmed units. The company framed the problem as isolated to a production run and offered free replacements.
“If undetected, incorrect low glucose readings over an extended period may lead to incorrect treatment decisions…These decisions may pose serious health risks, including potential injury or death,”
Abbott Diabetes Care (safety notice)
Abbott connected the reporting fault with plausible clinical responses—such as extra carbohydrate intake or skipped insulin doses—that could precipitate adverse outcomes, which is why the company advised immediate discontinuation of affected sensors.
“Of the seven people who died, all were located outside of the United States,”
NPR (news report)
The geographic distribution of reported deaths indicates that the most severe outcomes reported so far have occurred outside U.S. regulatory jurisdiction, though injuries were reported in the U.S. as well. Health systems elsewhere will need to coordinate with Abbott and regulators to notify impacted patients.
Unconfirmed
- Whether each of the seven reported deaths was directly caused by an incorrect sensor reading remains unconfirmed; individual case details and clinical investigations have not been published publicly.
- The precise technical fault on the single production line (for example, a specific component or step) has not been disclosed publicly; Abbott has cited internal testing but detailed root-cause documentation is pending.
Bottom Line
The recall affects millions of sensors and has been associated with serious reported harms, including seven deaths and hundreds of severe injuries; patients using FreeStyle Libre 3-family sensors should check their device status immediately and stop using any sensor confirmed as affected. Abbott’s offer of free replacements and its statement that production will continue are intended to limit disruption, but clinicians and health systems must act quickly to identify and advise affected patients.
In the near term, clinicians should ensure patients have reliable glucose data—through fingerstick testing or alternate CGMs—until a verified replacement is in hand. Regulators will likely seek detailed manufacturing records and corrective actions; patients and providers should follow official guidance from Abbott and the Food and Drug Administration for the latest instructions.
Sources
- NPR — (news report)
- FreeStyleCheck.com / Abbott — (official device check and company notice)
- U.S. Food and Drug Administration — (government regulator general recall information)